{"entity":{"id":"nct07110064","kind":"trial","name":"QL1706+Lenvatinib+AG Regimen as First-line Treatment for Advanced Metastatic Pancreatic Cancer","aka":[],"tldr":"A phase 2 trial of iparomlimab and tuvonralimab, lenvatinib and gemcitabine + nab-paclitaxel in pancreatic cancer, run by Du Juan, now recruiting.","summary":"QL1706+Lenvatinib+AG Regimen as First-line Treatment for Advanced Metastatic Pancreatic Cancer is a phase 2, interventional study registered as NCT07110064 by Du Juan, with a registry enrolment figure of 80 participants, started 2025-09-03 and due to reach its primary completion in 2027-08-31. Interventions recorded: QL1706+Lenvatinib+AG Regimen. Conditions listed: Advance Pancreatic Cancer. Primary outcome: Median Progression-Free Survival (mPFS). Pancreatic eligibility wording from the registry: \"Patients with histologically or cytologically confirmed advanced metastatic pancreatic cancer\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07110064","url":"https://clinicaltrials.gov/study/NCT07110064"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["metastatic-pdac"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["iparomlimab-tuvonralimab","lenvatinib","gemcitabine-nab-paclitaxel"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07110064","phase":"2","setting":"Iparomlimab and Tuvonralimab Injection (QL1706) in Combination With Lenvatinib and AG Regimen as First-line Treatment for Advanced Metastatic Pancreatic Cancer:A Prospective, Single-Arm, Multicenter, Phase II Clinical Study","sponsor":"Du Juan","enrolled":80,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07110064/","neighbours":{"cancer":[{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"gemcitabine-nab-paclitaxel","kind":"drug","name":"Gemcitabine + nab-paclitaxel","route":"/drugs/gemcitabine-nab-paclitaxel/"},{"id":"iparomlimab-tuvonralimab","kind":"drug","name":"Iparomlimab and tuvonralimab","route":"/drugs/iparomlimab-tuvonralimab/"},{"id":"lenvatinib","kind":"drug","name":"Lenvatinib","route":"/drugs/lenvatinib/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}